---
title: "UB-312 (alpha-synuclein vaccine): Parkinson's Drug Pipeline"
description: "An experimental vaccine designed to prompt the immune system to clear misfolded alpha-synuclein. Early studies show it triggers antibodies; whether it slows Parkinson's is unknown."
canonical_url: "https://parkinsonspathways.com/pipeline/ub-312-synuclein-vaccine"
development_stage: "Phase 1: first human safety tests"
last_updated: 2026-08-07
source: "Parkinson's Pathways"
---
# UB-312 (alpha-synuclein vaccine)

**Stage:** Phase 1  ·  **Type:** Disease-modifying

**Developer:** Vaxxinity

**How it works:** An experimental vaccine that trains the body's own immune system to make antibodies against the harmful, clumped form of alpha-synuclein.

**Target:** Aggregated alpha-synuclein

**Who it's for:** People with early Parkinson's and related synuclein disorders.

**Key trials:** NCT04075318, NCT05634876

**Last reviewed:** 2026-08-07


## What it is

Instead of infusing lab-made antibodies (as prasinezumab and cinpanemab did), UB-312 is an active vaccine: it prompts a person's own immune system to generate antibodies aimed specifically at the clumped, disease-associated form of alpha-synuclein, while sparing the normal form the body needs.

## Where it stands

A Phase 1 study reported that the vaccine was generally tolerated and did generate the intended antibodies, with early signs the antibodies reached the fluid around the brain. It remains an early-stage program; it has not been shown to change the course of Parkinson's.

## What the data shows so far

The Phase 1 program was a small, early-stage study whose pre-specified goals were safety and immunogenicity (whether the vaccine produces the intended antibodies), not whether it slows the disease. Peer-reviewed results (2024) reported target engagement and antibody generation in a small group of participants over the study's dosing period; the exact enrollment was modest, as is typical for a first-in-Parkinson's vaccine trial. Any effect on symptoms or progression is unproven and would require much larger, longer trials.

## What families should know

This is a novel take on the alpha-synuclein idea, and a vaccine could in theory be simpler than repeated infusions. But antibody approaches to alpha-synuclein have mostly disappointed so far, and this one is still at the earliest human stage.

## Caveats

Very early; a small Phase 1 focused on safety and immune response, not efficacy. Anti-alpha-synuclein antibody strategies have repeatedly failed to slow Parkinson's. Not approved and years from availability, if it works at all.

## Timeline

_Most recent first._

- **2024**, Peer-reviewed Phase 1 results report target engagement and antibody generation.
- **2019-2023**, Phase 1 studies in healthy volunteers and Parkinson's conducted.

## Sources

- [UB-312 Phase 1 study on ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT04075318)

_Last reviewed: 2026-08-07._

## More

- [Back to the Parkinson's drug pipeline](https://parkinsonspathways.com/pipeline)
- [Browse all recruiting trials](https://parkinsonspathways.com/trials)